OSAM
SCPH

O'Shaughnessy Asset Management’s scPharmaceuticals SCPH Stock Holding History

O'Shaughnessy Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21
Closed – – 2452
2020
Q4 		$0 Buy
+21
New +$164 ﹤0.01% 2213
2020
Q1 		– Sell
-1,655
Closed -$9K – 1741
2019
Q4 		$9K Buy
+1,655
New +$8.47K ﹤0.01% 1331

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

O'Shaughnessy Asset Management's SCPH Position: Q1 2021 in Review

O'Shaughnessy Asset Management sold out of scPharmaceuticals (SCPH) in Q1 2021, closing a stake of 21 shares.

O'Shaughnessy Asset Management first reported a position in SCPH in Q4 2019 and held it in 2 quarters. The position peaked at $9K in Q4 2019. 46 funds tracked by Wall St. Rank hold SCPH as of Q1 2021.

  • O'Shaughnessy Asset Management reported no remaining scPharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 21 scPharmaceuticals shares in Q1 2021.
  • O'Shaughnessy Asset Management first reported a position in scPharmaceuticals in Q4 2019 and held it in 2 quarters.
  • O'Shaughnessy Asset Management's scPharmaceuticals position peaked at $9K in Q4 2019.
  • 46 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2021, filed 14 May 2021.